Welcome to our dedicated page for Mdxhealth Sa SEC filings (Ticker: MDXH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MDxHealth SA (MDXH) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a foreign private issuer. MDxHealth files annual reports on Form 20-F and current reports on Form 6-K under the Securities Exchange Act of 1934. These documents offer detailed information on its precision diagnostics business for prostate cancer and other urologic diseases, its financial condition, and material corporate events.
Form 20-F filings contain audited financial statements prepared under International Financial Reporting Standards (IFRS), along with sections on business description, risk factors, management’s discussion and analysis, and details of MDxHealth’s molecular diagnostic portfolio. For a company that derives revenue from clinical laboratory service testing and out-licensing of its DNA methylation platform and biomarkers, these annual reports are a key resource for understanding revenue composition, research and development spending, and acquisition accounting.
Form 6-K reports are used by MDxHealth to furnish press releases and interim reports, including quarterly and half-year financial results, acquisition announcements such as the Exosome Diagnostics transaction, amendments to earnout obligations related to the GPS prostate cancer business, management and board changes, and other significant updates. Some 6-K exhibits, such as interim reports, may be incorporated by reference into the company’s shelf registration statements on Form F-3, as noted in the filings.
On Stock Titan, MDXH filings are updated as they appear on EDGAR and are accompanied by AI-powered summaries that highlight the main points in complex documents. Users can quickly scan annual 20-F reports, interim 6-Ks, and related exhibits to identify information on MDxHealth’s precision diagnostics operations, risk disclosures, financing arrangements, and acquisition-related commitments, without reading each filing in full.
MDxHealth reported strong growth for the year ended December 31, 2025, with revenue up 20% to
Full-year gross profit rose 26% to
The company reduced its operating loss to
For 2026, MDxHealth guides revenue to
MDxHealth is registering up to
The company is a commercial-stage precision diagnostics business focused on urologic cancers, with core tests ExoDx, Confirm mdx and GPS. It qualifies as both an emerging growth company and a foreign private issuer, using reduced U.S. reporting requirements.
Risk factors emphasize continued losses and liquidity pressure. As of December 31, 2024, MDxHealth had an accumulated deficit of
MDxHealth reports on its acquisition of Exosome Diagnostics and an amended earnout arrangement for a prior GPS transaction. The company agreed to acquire Exosome Diagnostics, including the ExoDx prostate cancer test and CLIA lab, for up to $15 million, with about $5 million in stock at closing and four subsequent annual instalments of $2.5 million each, partly in cash and partly in cash or stock at MDxHealth’s discretion.
Audited 2025 financials for Exosome Diagnostics show sales of $27.3 million and a net loss of $86.5 million, driven largely by impairment charges. MDxHealth also amended the GPS acquisition earnout with Exact Sciences, rescheduling remaining payments to $15.0 million in 2026, $18.0 million in 2027 and $21.5 million in 2028, and issuing warrants for 3 million MDxHealth shares at an exercise price of $5.265 per share.
MDxHealth SA received an updated ownership report showing that Genomic Health, Inc., a Delaware company and wholly owned subsidiary of Exact Sciences Corporation, beneficially owns a total of 6,441,171 ordinary shares of MDxHealth. This total includes 2,441,171 ordinary shares directly owned and warrants or contractual rights to purchase an additional 4,000,000 ordinary shares.
The filing states this represents 12.0% of MDxHealth’s ordinary shares, based on 49,497,334 ordinary shares issued and outstanding as described in MDxHealth’s Form F-3 registration statement filed on December 29, 2025. Exact Sciences may be deemed to beneficially own the shares held by Genomic Health, and the reporting persons certify that the securities are not held for the purpose of changing or influencing control of MDxHealth.
MDxHealth SA reported preliminary 2025 revenue of about $109 million, with fourth quarter revenue of about $30.5 million, reflecting year-over-year growth of 21% and 23%, respectively. In the quarter, the company billed 11,201 tissue-based and 27,486 liquid-based units, while full-year volumes reached 49,180 tissue-based and 71,920 liquid-based units, with especially strong liquid-based growth. Year-end cash was $29.0 million.
For 2026, MDxHealth guides revenue to $137–140 million, implying growth of about 26–28%, and targets an adjusted EBITDA margin run rate of 10% exiting 2026. The company also amended the earnout related to its 2022 GPS acquisition from Exact Sciences, deferring payments into three installments of $15.0 million in 2026, $18.0 million in 2027, and $21.5 million in 2028, and agreed to issue warrants for 3 million shares at an exercise price of $5.265 per share.
MDxHealth SA submitted a Form 6-K as a foreign private issuer to provide its 2025 Interim Report to investors. The interim report is attached as Exhibit 99.1 and contains the company’s detailed mid-year financial and operational information.
The company also formally confirms the accuracy of its previously released preliminary financial results that were furnished in a prior Form 6-K on August 5, 2025. The interim report is incorporated by reference into MDxHealth’s existing shelf registration statements on Form F-3, meaning those registration statements now include the latest interim information.